Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
Researchers polled people on HIV treatment about their preferences for various forms of long-acting antiretrovirals.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.
One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.
HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.
A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.
A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.
This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.